Autoimmune antibody in a hemorrhagic patient interacts with thrombin- activated factor XIII in a unique manner

Laszlo Lorand*, Pauline T. Velasco, S. N Prasanna Murthy, Phil Lefebvre, David Green

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Without a prior history of hemorrhagic disease, a 62-year-old man suffered recurrent episodes of bleeding. Solubility of the patient's clot in 5 mol/L urea indicated a problem with fibrin stabilization. The transamidase activity potential of factor XIII, measured the incorporation of radioactive putrescine into N,N-dimethylcasein as test substrate, was 62% of control, close to the normal range of values. Examination of the patient's clot from recalcified plasma sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that essentially none of the α chains and only about two thirds of the Y chains of fibrin became cross-linked under conditions where both were fully cross-linked in the controls. An antibody to factor XIII was isolated which, although recognizing the recombinant rA2 subunits, as well as the virgin A2B2 plasma ensemble, showed a 100-fold greater affinity for the thrombin-activated rA2' and A2'B2 forms of the zymogen, suggesting that the latter would be its main target during coagulation. Furthermore, the patient's IgG has an ability, never seen before, for inducing an enzymatically active configuration in the thrombin-activated zymogen in the absence of Ca2+.

Original languageEnglish (US)
Pages (from-to)909-917
Number of pages9
Issue number3
StatePublished - Feb 1 1999

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Autoimmune antibody in a hemorrhagic patient interacts with thrombin- activated factor XIII in a unique manner'. Together they form a unique fingerprint.

Cite this